Management of Older Men With Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity

Seminars in Radiation Oncology

Volumn 22, Issue 4, 2012, Pages 284-294

  Hoffman, Karen E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUCOSE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

AGE; AGED; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; BLOOD PRESSURE MONITORING; BONE DENSITY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COGNITION; COMORBIDITY; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; ELDERLY CARE; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; FALLING; FATIGUE; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPOGONADISM; INCONTINENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LEAN BODY WEIGHT; LIFE EXPECTANCY; MALE; MUSCLE WEAKNESS; PATIENT CARE; PATIENT COUNSELING; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RESISTANCE TRAINING; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SMOKING CESSATION; SOCIAL SUPPORT; URETHRA STRICTURE; VITAMIN SUPPLEMENTATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; COMORBIDITY; DECISION MAKING; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84866317945     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.05.005     Document Type: Review

References (117)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29.
2. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review 1975-2008 (Based on November 2010 SEER data submission, posted to the SEER web site 2011) Bethesda, MD, National Cancer Institute, Accessed December 1, 2011. http://seer.cancer.gov/csr/1975_2008/.
3. Shao Y.H., Demissie K., Shih W., et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009, 101:1280-1283.
4. Wolff J.L., Starfield B., Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002, 162:2269-2276.
5. Albertsen P.C., Fryback D.G., Storer B.E., et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996, 156:127-132.
6. Tewari A., Johnson C.C., Divine G., et al. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004, 171:1513-1519.
7. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106-2131.
8. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V.4, Accessed September 6, 2011. http://www.nccn.org.
9. NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology V.2, Accessed January 1, 2012. http://www.nccn.org.
10. Alibhai S.M., Leach M., Tomlinson G.A., et al. Is there an optimal comorbidity index for prostate cancer?. Cancer 2008, 112:1043-1050.
11. Litwin M.S., Greenfield S., Elkin E.P., et al. Assessment of prognosis with the total illness burden index for prostate cancer: Aiding clinicians in treatment choice. Cancer 2007, 109:1777-1783.
12. Boulos D.L., Groome P.A., Brundage M.D., et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 2006, 106:1804-1814.
13. Alibhai S.M., Leach M., Tomlinson G., et al. 30-Day mortality and major complications after radical prostatectomy: Influence of age and comorbidity. J Natl Cancer Inst 2005, 97:1525-1532.
14. Budäus L., Bolla M., Bossi A., et al. Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol 2012, 61:112-127.
15. Chen A.B., D'Amico A.V., Neville B.A., et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006, 24:5298-5304.
16. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
17. Koch M.O., Miller D.A., Butler R., et al. Are we selecting the right patients for treatment of localized prostate cancer?. Results of an actuarial analysis. Urology 1998, 51:197-202.
18. Krahn M.D., Bremner K.E., Asaria J., et al. The ten-year rule revisited: Accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 2002, 60:258-263.
19. Walz J., Gallina A., Perrotte P., et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007, 100:1254-1258.
20. Cowen M.E., Halasyamani L.K., Kattan M.W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006, 175:99-103.
21. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007, 25:3576-3581.
22. Lughezzani G., Briganti A., Karakiewicz P.I., et al. Predictive and prognostic models in radical prostatectomy candidates: A critical analysis of the literature. Eur Urol 2010, 58:687-700.
23. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001, 285:2750-2756.
24. Period Life Table, 2007 Social Security Administration, Accessed December 1, 2011. http://www.ssa.gov/oact/STATS/table4c6.html.
25. Alibhai S.M., Krahn M.D., Fleshner N.E., et al. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int 2004, 94:303-306.
26. Moul J.W., Wu H., Sun L., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: An overview of the department of Defense Center for Prostate Disease Research national database. Surgery 2002, 132:213-219.
27. Yan Y., Carvalhal G.F., Catalona W.J., et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000, 88:1122-1130.
28. Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
29. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009, 302:1202-1209.
30. Alibhai S.M., Naglie G., Nam R., et al. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 2003, 21:3318-3327.
31. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
32. Nguyen P.L., Chen M.H., Renshaw A.A., et al. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: Implications for screening recommendations. Int J Radiat Oncol Biol Phys 2010, 76:337-341.
33. Hoffman K.E., Chen M.H., Moran B.J., et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 2010, 116:2590-2595.
34. Harlan L.C., Potosky A., Gilliland F.D., et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 2001, 93:1864-1871.
35. Roberts C.B., Albertsen P.C., Shao Y.H., et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med 2011, 124:235-243.
36. Schwartz K.L., Alibhai S.M., Tomlinson G., et al. Continued undertreatment of older men with localized prostate cancer. Urology 2003, 62:860-865.
37. Bechis S.K., Carroll P.R., Cooperberg M.R. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011, 29:235-241.
38. Krakowsky Y., Loblaw A., Klotz L. Prostate cancer death of men treated with initial active surveillance: Clinical and biochemical characteristics. J Urol 2010, 184:131-135.
39. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
40. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
41. Marr P.L., Elkin E.P., Arredondo S.A., et al. Comorbidity and primary treatment for localized prostate cancer: Data from CaPSURE. J Urol 2006, 175:1326-1331.
42. Shavers V.L., Brown M.L., Potosky A.L., et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 2004, 19:146-155.
43. Harlan S.R., Cooperberg M.R., Elkin E.P., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 2003, 170:1804-1807.
44. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004, 22:2141-2149.
45. Role of active surveillance in the management of men with localized prostate cancer NIH State-of-the-Science Conference, Accessed January 16, 2012. http://consensus.nih.gov/2011/docs/prostate/ASPC%20Final%20Draft%20Statement.pdf.
46. Daskivich T.J., Chamie K., Kwan L., et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011, 117:2058-2066.
47. Walz J., Montorsi F., Jeldres C., et al. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: A population-based analysis of 9208 consecutive cases. BJU Int 2008, 101:826-832.
48. Novara G., Ficarra V., D'Elia C., et al. Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. J Urol 2010, 184:1028-1033.
49. Wei J.T., Dunn R.L., Marcovich R., et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000, 164:744-748.
50. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. JAMA 2000, 283:354-360.
51. Elliott S.P., Meng M.V., Elkin E.P., et al. Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE. J Urol 2007, 178:529-534. discussion 534.
52. Kao T.C., Cruess D.F., Garner D., et al. Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urol 2000, 163:858-864.
53. Lee D.J., Cheetham P., Badani K.K. Predictors of early urinary continence after robotic prostatectomy. Can J Urol 2010, 17:5200-5205.
54. Alemozaffar M., Regan M.M., Cooperberg M.R., et al. Prediction of erectile function following treatment for prostate cancer. Jama 2011, 306:1205-1214.
55. Karakiewicz P.I., Bhojani N., Neugut A., et al. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. J Sex Med 2008, 5:919-927.
56. Konety B.R., Cowan J.E., Carroll P.R., et al. Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 2008, 179:1797-1803. discussion 1803.
57. Tward J, Shrieve D: Patterns of care for localized prostate cancer stratified by risk group and age at diagnosis in the United States: Proceedings of the American Society for Radiation Oncology 53rd Annual Meeting, Abstract 204, 2011.
58. Schymura M.J., Kahn A.R., German R.R., et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: Results from the CDC-NPCR patterns of Care study (PoC1). BMC Cancer 2010, 10:152.
59. Tucker S.L., Dong L., Bosch W.R., et al. Late rectal toxicity on RTOG 94-06: Analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys 2010, 78:1253-1260.
60. Choe K.S., Jani A.B., Liauw S.L. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: How significant is the bleeding toxicity?. Int J Radiat Oncol Biol Phys 2010, 76:755-760.
61. Herold D.M., Hanlon A.L., Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999, 43:475-479.
62. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
63. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37:3-11.
64. Koper P.C., Heemsbergen W.D., Hoogeman M.S., et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1072-1082.
65. Liu M., Pickles T., Agranovich A., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 2004, 58:59-67.
66. Fiorino C., Fellin G., Rancati T., et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008, 70:1130-1137.
67. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
68. Pinkawa M., Gagel B., Piroth M.D., et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009, 55:227-234.
69. Arredondo S.A., Elkin E.P., Marr P.L., et al. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE. Urology 2006, 67:559-565.
70. Daskivich T.J., van de Poll-Franse L.V., Kwan L., et al. From bad to worse: Comorbidity severity and quality of life after treatment for early-stage prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:320-327.
71. Thong M.S., van de Poll-Franse L., Hoffman R.M., et al. Diabetes mellitus and health-related quality of life in prostate cancer: 5-Year results from the prostate cancer outcomes study. BJU Int 2011, 107:1223-1231.
72. Stone P., Hardy J., Huddart R., et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000, 36:1134-1141.
73. Lee H., McGovern K., Finkelstein J.S., et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104:1633-1637.
74. Smith M.R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004, 63:742-745.
75. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
76. Williams M.B., Hernandez J., Thompson I. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: How hormonal therapy in prostate cancer affects muscular strength. J Urol 2005, 173:1067-1071.
77. Bylow K., Mohile S.G., Stadler W.M., et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?. A conceptual review. Cancer 2007, 110:2604-2613.
78. Keogh J.W., Macleod R.D. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. J Pain Symptom Manage 2012, 43:96-110.
79. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361-2367. discussion 2367.
80. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998, 83:1561-1566.
81. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
82. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
83. Wolinsky F.D., Fitzgerald J.F., Stump T.E. The effect of hip fracture on mortality, hospitalization, and functional status: A prospective study. Am J Public Health 1997, 87:398-403.
84. Falls Among Older Adults: An Overview Center for Disease Control and Prevention, Division of Unintentional Injury Prevention, Last Updated, September 16, 2011, Accessed January 15, 2012. http://www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html.
85. Tinetti M.E. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003, 348:42-49.
86. Bone Health and Osteoporosis: A Report of the Surgeon General 2004, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD.
87. Gralow J.R., Biermann J.S., Farooki A., et al. NCCN Task Force report: Bone health in cancer Care. J Natl Compr Canc Netw 2009, 7(suppl 3):S1-S32. quiz S33-S35.
88. Dockery F., Bulpitt C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia. Clin Sci (Lond) 2003, 104:195-201.
89. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261-4267.
90. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
91. Eri L.M., Urdal P., Bechensteen A.G. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100-104.
92. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
93. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516-1524.
94. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493-1500.
95. Nanda A., Chen M.H., Braccioforte M.H., et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302:866-873.
96. Alibhai S.M., Duong-Hua M., Sutradhar R., et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009, 27:3452-3458.
97. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
98. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27:92-99.
99. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 2008, 54:816-823.
100. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
101. Nguyen P.L., Je Y., Schutz F.A., et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 2011, 306:2359-2366.
102. Hayes J.H., Chen M.H., Moran B.J., et al. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010, 106:979-985.
103. Nguyen P.L., Chen M.H., Beckman J.A., et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2011, 82:1411-1416.
104. Nguyen P.L., Chen M.H., Goldhaber S.Z., et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 2011, 117:406-413.
105. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-Year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
106. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008, 299:289-295.
107. Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-Year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
108. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
109. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
110. Jones C.U., Hunt D., McGowan D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
111. Nguyen P.L., Chen M.H., Beard C.J., et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010, 77:1046-1052.
112. Bian S.X., Kuban D.A., Levy L.B., et al. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 2012 Feb 21, [Epub ahead of print].
113. (RTOG 0815) A phase III prospective Randomized Trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer Accessed December 27, 2011. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815.
114. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
115. D'Amico A.V. Is long-term androgen suppression right for everyone with locally advanced prostate cancer?. Lancet Oncol 2010, 11:1016-1017.
116. Wilke D.R., Parker C., Andonowski A., et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 2006, 97:963-968.
117. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009, 75:10-15.